



EUROPEAN PARLIAMENT

2014 - 2019

---

*Committee on the Environment, Public Health and Food Safety*

---

**2014/2102(DEC)**

12.12.2014

# **AMENDMENTS**

## **1 - 3**

**Draft opinion**  
**Giovanni La Via**  
(PE541.523v01-00)

Discharge 2013: European Medicines Agency  
(2014/2102(DEC))

AM\1043545EN.doc

PE544.370v01-00

**EN**

*United in diversity*

**EN**

AM\_Com\_NonLegOpinion

**Amendment 1**  
**Karin Kadenbach**

**Draft opinion**  
**Paragraph 2**

*Draft opinion*

2. Notes that in 2013, out of the total resources available to the Agency of EUR 251 560 000, 16,3% (EUR 40 937 454) had been EU budget contributions (including *a* special contribution for orphan medicines fee reductions of EUR 6 509 360); likes to stress that this amount represents 0.027% of the overall EU budget;

*Amendment*

2. Notes that in 2013, out of the total resources available to the Agency of EUR 251 560 000, 16,3% (EUR 40 937 454) had been EU budget contributions (including *an important and essential* special contribution for orphan medicines fee reductions of EUR 6 509 360); likes to stress that this amount represents 0.027% of the overall EU budget;

Or. de

**Amendment 2**  
**Julie Girling**

**Draft opinion**  
**Paragraph 3 a (new)**

*Draft opinion*

*Amendment*

*3a. Welcomes that a new procedure entered into force in 2014 which corrected the former irregular practice, whereby the Agency paid education contributions directly to schools for staff, in contravention of the Staff Regulations;*

Or. en

**Amendment 3**  
**Benedek Jávor**

**Draft opinion**  
**Paragraph 4**

*Draft opinion*

4. Reiterates the important role of the Agency in protecting and promoting public and animal health by assessing and supervising medicines for human or veterinary use; welcomes the policy on the handling of conflict of interests, last updated and endorsed by the Management Board in March 2012;

*Amendment*

4. Reiterates the important role of the Agency in protecting and promoting public and animal health by assessing and supervising medicines for human or veterinary use; welcomes the ***annual declarations and the*** policy on the handling of conflict of interests, last updated and endorsed by the Management Board in March 2012, ***and invites the Agency to further strengthen its policy on the management and handling of conflicts of interests in order to ensure independence and transparency in all work areas of the Agency;***

Or. en